Apoptosis, cell proliferation and TOPRO-3 viability assay
Apoptotic rate of AML cells was assessed using FITC-conjugated AnnexinV In order to discriminate live cell population, samples were stained with TO-PRO-3 (1µM) and analyzed by FACS. Relative cell proliferation were expressed as the percentage of CFSE median fluorescence of treated cells compared to that of cells treated with the specific vehicle.
MayGrunwald-Giemsa staining
We applied this method to study whether the treatments with GSIs and Idarubicin affected hBM-MSCs* morphology. Briefly, adherent hBM-MSCs* were washed with PBS to remove AML cells, then cells were stained with three decreasing concentrations of MayGrunwald-Giemsa solution, i.e. 3 minutes with pure 100% MayGrunwald, 2 minutes with 1/3 diluted MayGrunwald solution, and finally 15 minutes with 1/10 diluted Giemsa solution.
Cells were then washed with distillated water and dried at room temperature. Stained cells were acquired with Axiovert Z1 Observer Microscope (Zeiss). (anti-Notch2), α-N3 (anti-Notch3), α-N4 (anti-Notch4). All blocking antibodies were used at a final concentration of 5µg/ml. Cell viability was analyzed through AnnexinV/PI assay. Data are expressed as mean ± SEM of 3 independent experiments: *p<0.05, **p<0.01, ***p<0.001. Table S4 . GSI-XII abrogates hBM-MSC-mediated chemoresistance.
Viability of AML cells in culture or co-culture with hBM-MSCs in presence of either Ara-C (10µM), Etoposide (10µM) or Idarubicin (0.5µM) and increasing concentrations of GSI-XII.
After 48 hours, cells were collected and analyzed by AnnexinV/PI assay. Data are expressed as mean ± SEM of 3 independent experiments. Statistical analysis was performed with oneway Anova comparing all the culture conditions with AML + hBM-MSCs in presence of DMSO. *p<0.05, **p<0.01, ***p<0.001.
